IMTX Immatics NV: Enterprise Value-to-Revenue Multiple

Public company logo of immatics.com (IMTX)

The intellectual capital of Immatics N.V. (IMTX) is based on the discovery of tumor targets for T-cell therapy. The EV/Revenue multiple demonstrates stable dynamics, with the metric currently standing at 8072.08. Financial stability is supported by payments from pharma partners and flawless cold chain control during drug delivery, which guarantees high profitability and protects the company from market volatility.

Company Value to Revenue: Immatics NV (IMTX) for 11/23/2025 - 11/20/2026

immatics.com - analytical breakdowns and key metrics (IMTX)

- share price and consensus valuation forecast:
Initial company analysis:Immatics N.V. IMTX
Product sample of Immatics N.V.

The innovative T-cell receptor ecosystem of Immatics N.V. (IMTX) creates high added value within the precision oncology segment. The current EV/Sales ratio reflects the enterprise value of the business, accounting for net debt relative to generated revenue. This metric allows for an assessment of the capitalization efficiency of the company's technological advantage without distortions from debt load. The indicator serves as a filter to separate fundamental growth from speculative volatility. Analyzing the trend of the current EV/Sales ratio helps determine the fair value of the assets.

Competitor analysis for Immatics N.V.

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple XNCR (Xencor)|Business Value to Revenue CMPX|replimune.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Lyell Pharma|Innate Pharma S.A. (IPHA) - Enterprise Value-to-Revenue Ratio|Pyxis Oncology Inc. - Business Value to Revenue|CGEN (Compugen Limited) - EV/Sales Multiple|EV/Sales Multiple IO Biotech Inc|Enterprise Value-to-Revenue Ratio Sutro Biopharma (STRO)|INKT: Enterprise Value to Sales Volume|Werewolf Therapeutics, Inc. - Company Value to Revenue|Immix (IMMX) - Enterprise Value-to-Revenue Multiple|ALX Oncology Holdings Inc. - EV/Sales Multiple|CUE - EV/Sales Multiple|PDSB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP